← Calendar
Readoutin 164d
Novartis Pharmaceuticals — Remibrutinib Dose A
Phase 3 primary completion: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1).
- Date
- May 2027
- Type
- Readout
- Indication
- Hidradenitis Suppurativa
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Novartis Pharmaceuticals
May2027
Readoutin 164d
Novartis Pharmaceuticals — Inclisiran sodium 300 mgPhase 3 primary completion: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease.
Apr2027
Readoutin 134d
Novartis Pharmaceuticals — IanalumabPhase 3 primary completion: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1).
Mar2027
Readoutin 103d
Novartis Pharmaceuticals — IanalumabPhase 3 primary completion: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1).
Feb2027
Readoutin 75d
Novartis Pharmaceuticals — RemibrutinibPhase 3 primary completion: A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines.
Feb2027
Readoutin 75d
Novartis Pharmaceuticals — everolimusPhase 3 primary completion: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment.